Minimal Stimulation IVF Is Cheaper Per Cycle, but the Savings Case Is Unsettled

An IFFS webinar on minimal stimulation IVF began with a knowledge quiz. It ended when a patient advocate urged clinicians to keep the person in the chair in mind. In between, a health economist set out why questions of cost in assisted reproduction lack a simple answer.

The session carried the title “Minimal or Normal Stimulation in ART: Health Economics and Patient Perspective.” The International Federation of Fertility Societies organized the event, and Luca Gianaroli moderated. He directs the federation’s global educational programs. Mark Connolly, a health economist with more than 22 years of experience across academia, consulting and industry, presented the economics section. Barbara Collura, president and CEO of RESOLVE: The National Infertility Association in the United States, spoke on the patient perspective.

Efficiency, perspective and the questions health economists ask

Connolly opened with scarcity. Health systems face finite resources in every country. The task is to rationalize spending and identify the combination that produces the best outcomes within a budget while accounting for equity. Perspective comes first, he said, because an analysis can be prepared for a national payer, a government, a private insurer or the couple paying out of pocket, and the result changes with the payer.

Ad

“There’s limited resources everywhere. It doesn’t matter which country you’re in. So it’s really about trying to rationalize the spending that you have and trying to find the optimal solution to optimize outcomes in relationship to your budget.”

He divided the field into two areas. Allocative efficiency considers which health needs receive funding, weighing breast cancer screening against colorectal care, cardiovascular medicine or IVF. Technical efficiency compares treatment options for the same patient, the setting where most clinicians encounter health economics, and the metric used is incremental cost per live birth. Few clinicians see the first type of study, he said, yet it determines where a health ministry directs its funds.

The fiscal side falls under cost-benefit analysis rather than cost-effectiveness. It starts with an awkward result for households. Children rarely represent a sound financial investment for the couple that has them, because wages fall, time leaves the workforce and skills erode during career breaks. That is why governments adopt pronatalist policies that reduce the penalty.

Children as a fiscal asset, and the Bank of Italy’s arithmetic

For governments the sign reverses. Connolly cited a Bank of Italy analysis that projected net discounted lifetime tax contributions from children born in 2006 at roughly 180,000. Italian births continue to decline, so each later cohort bears a heavier load than the one before it, and children conceived without medical assistance end up paying for those never born. His own modeling compares lifetime taxes and transfers for parents and childless couples and finds that parents pay less.

Applied to fertility treatment, the framework yields a fiscal return on investment. A UK analysis from around 2010 showed that an IVF-conceived child cost the state roughly 12,000 pounds more than a naturally conceived child. At about 12,000 pounds per live birth for younger women, the return reached roughly ninefold, so every pound spent returned nine pounds over the child’s working life. He presented the finding as the sort of evidence that can decide whether governments maintain investment in future generations through fertility coverage, and he noted that most governments have yet to determine how to set funding policies for assisted reproduction.

Singapore provided a test case. The government subsidized between 30% and 40% of each cycle and asked whether to cover a larger share or simply pay for more cycles. The modeling indicated that extending cover from three cycles to six was not a sound fiscal use of money, whereas spending more on earlier cycles so couples reach a live birth sooner was. An Italian analysis applied the same logic in reverse, estimating the number of couples left untreated given clinic supply and current practice, and concluded that the government loses substantial revenue it never collects.

Where minimal stimulation IVF sits in the evidence

Connolly offered no overall winner. Each case differs, he said, because the choice depends on diagnosis, the doctor, the embryologist, what a couple can tolerate and local practice as much as the published literature.

“I cannot give you a firm conclusion whether minimal or normal is the optimal path to follow. What I’m trying to do is show you a framework that you can look at, because I do believe that every situation is very unique.”

What the published studies showed was narrower. He found no statistically significant difference in pregnancy outcomes between mild and conventional stimulation, less treatment-related stress and better tolerance with mild protocols, and a lower cost per treatment cycle. Fewer oocytes produce fewer embryos, so repeat cycles and frozen embryo transfers must enter the model, and the patient population in front of the clinician, whether poor, normal or high responders, alters the arithmetic.

“There’s not really evidence of a statistically significant difference in pregnancy outcomes between mild and conventional.”

He argued for the cumulative live birth rate as the outcome that matters, rather than the result of a single cycle, and he warned that cost-effectiveness analysis stalls on a question no data set has settled: how much more a society is willing to pay for one additional live birth. Below that threshold a treatment appears acceptable; above it the treatment does not, and the threshold itself reflects a judgment on value rather than a figure data can supply.

What the webinar’s polls showed

IFFS ran the same five multiple-choice questions before and after the lectures. The answers moved most on the fiscal questions. Asked which analytic approach applies, participants chose cost-effectiveness 33% of the time beforehand and 53% afterwards, while cost-benefit fell from 36% to 26%. On the projected fiscal return of ART-conceived children, the preferred answer climbed from 61% to 95%. On which factors shape a patient’s emotional burden, “all of them” rose from 81% to 95%. On what matters most to IVF patients, delivering a healthy baby went from 72% to 84%.

Gianaroli drew the conclusion himself, telling the audience that clinicians included, they had been short of information, most of it in health economics, and that their thinking shifted once that information arrived.

“We as clinicians, we as attendees have a lack of information, most probably mainly in the health economics. And once that we are instructed, or once that we get the information, also our way of thinking changes quite dramatically.”

He also pushed back on the idea that respect runs in one direction. Patients owe it to clinicians as well, he said, and a clinic is not a shop where a patient arrives to buy an outcome.

“The relationship between clinicians and patients cannot be only one side in terms of respect. It has to be both, otherwise the risk is to jeopardize the entire system.”

Source: IFFS webinar, “Minimal or Normal Stimulation in ART: Health Economics and Patient Perspective”; video recording on Vimeo.